Search

Your search keyword '"Skenders, Girts"' showing total 30 results
Start Over Author "Skenders, Girts"
30 results on '"Skenders, Girts"'

1. Toll-Like Receptor 1 Locus Re-examined in a Genome-Wide Association Study Update on Anti–Helicobacter pylori IgG Titers

Author

Lam, Suk Yee, Mommersteeg, Michiel C., Yu, Bingting, Broer, Linda, Spaander, Manon C.W., Frost, Fabian, Weiss, Stefan, Völzke, Henry, Lerch, Markus M., Schöttker, Ben, Zhang, Yan, Stocker, Hannah, Brenner, Hermann, Levy, Daniel, Hwang, Shih-Jen, Wood, Alexis C., Rich, Stephen S., Rotter, Jerome I., Taylor, Kent D., Tracy, Russell P., Kabagambe, Edmond K., Leja, Marcis, Klovins, Janis, Peculis, Raitis, Rudzite, Dace, Nikitina-Zake, Liene, Skenders, Girts, Rovite, Vita, Uitterlinden, André, Kuipers, Ernst J., Fuhler, Gwenny M., Homuth, Georg, and Peppelenbosch, Maikel P.

Published
2022
Full Text
View/download PDF

3. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study

Author

Zignol, Matteo, Cabibbe, Andrea Maurizio, Dean, Anna S, Glaziou, Philippe, Alikhanova, Natavan, Ama, Cecilia, Andres, Sönke, Barbova, Anna, Borbe-Reyes, Angeli, Chin, Daniel P, Cirillo, Daniela Maria, Colvin, Charlotte, Dadu, Andrei, Dreyer, Andries, Driesen, Michèle, Gilpin, Christopher, Hasan, Rumina, Hasan, Zahra, Hoffner, Sven, Hussain, Alamdar, Ismail, Nazir, Kamal, S M Mostofa, Khanzada, Faisal Masood, Kimerling, Michael, Kohl, Thomas Andreas, Mansjö, Mikael, Miotto, Paolo, Mukadi, Ya Diul, Mvusi, Lindiwe, Niemann, Stefan, Omar, Shaheed V, Rigouts, Leen, Schito, Marco, Sela, Ivita, Seyfaddinova, Mehriban, Skenders, Girts, Skrahina, Alena, Tahseen, Sabira, Wells, William A, Zhurilo, Alexander, Weyer, Karin, Floyd, Katherine, and Raviglione, Mario C

Published
2018
Full Text
View/download PDF

5. Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease

Author

Nikolayevskyy, Vladyslav, Miotto, Paolo, Pimkina, Edita, Balabanova, Yanina, Kontsevaya, Irina, Ignatyeva, Olga, Ambrosi, Alessandro, Skenders, Girts, Ambrozaitis, Arvydas, Kovalyov, Alexander, Sadykhova, Anna, Simak, Tatiana, Kritsky, Andrey, Mironova, Svetlana, Tikhonova, Olesya, Dubrovskaya, Yulia, Rodionova, Yulia, Cirillo, Daniela, and Drobniewski, Francis

Published
2015
Full Text
View/download PDF

7. Development and use of an ESBL coding gene panel in patients undergoing first-line eradication therapy for Helicobacter pylori

Author

Gudra, Dita, primary, Silamikelis, Ivars, additional, Pjalkovskis, Janis, additional, Danenberga, Ilva, additional, Pupola, Darta, additional, Skenders, Girts, additional, Ustinova, Maija, additional, Megnis, Kaspars, additional, Leja, Marcis, additional, Vangravs, Reinis, additional, and Fridmanis, Davids, additional

Published
2022
Full Text
View/download PDF

8. Profiles of Volatile Biomarkers Detect Tuberculosis from Skin (Adv. Sci. 15/2021)

Author

Vishinkin, Rotem, primary, Busool, Rami, additional, Mansour, Elias, additional, Fish, Falk, additional, Esmail, Ali, additional, Kumar, Parveen, additional, Gharaa, Alaa, additional, Cancilla, John C., additional, Torrecilla, Jose S., additional, Skenders, Girts, additional, Leja, Marcis, additional, Dheda, Keertan, additional, Singh, Sarman, additional, and Haick, Hossam, additional

Published
2021
Full Text
View/download PDF

9. Profiles of Volatile Biomarkers Detect Tuberculosis from Skin

Author

Haick, Hossam, primary, Vishinkin, Rotem, additional, Busool, Rami, additional, Mansour, Elias, additional, Fish, Falk, additional, Esmail, Aliasgar, additional, Kumar, Parveen, additional, Garaa, Alaa, additional, Cancilla, John, additional, Torrecilla, Jose, additional, Skenders, Girts, additional, Leja, Marcis, additional, Dheda, Keertan, additional, and Singh, Sarman, additional

Published
2020
Full Text
View/download PDF

13. Analysis of Mycobacterium tuberculosis genetic lineages circulating in Riga and Riga region, Latvia, isolated between 2008 and 2012

Author

Pole, Ilva, primary, Trofimova, Julija, additional, Norvaisa, Inga, additional, Supply, Philip, additional, Skenders, Girts, additional, Nodieva, Anda, additional, Ozere, Iveta, additional, Riekstina, Vija, additional, Igumnova, Viktorija, additional, Storozenko, Jelena, additional, Jansone, Inta, additional, Viksna, Ludmila, additional, and Ranka, Renate, additional

Published
2020
Full Text
View/download PDF

15. Multidrug-resistant tuberculosis detection, Latvia

Author

Skenders,Girts, Fry, Alicia M., Prokopovica, Inga, Greckoseja, Silvija, Broka, Lonija, Metchock, Beverly, Holtz, Timothy H., Wells, Charles D., and Leimane, Vaira

Subjects
Tuberculosis, Mycobacterial infections, Drug resistance
Abstract

To improve multidrug-resistant tuberculosis (MDR-TB) detection, we successfully introduced the rpoB gene mutation line probe assay into the national laboratory in Latvia, a country with epidemic MDR-TB. The assay detected [...]

Published
2005

16. Generation of a novel next-generation sequencing-based method for the isolation of new human papillomavirus types

Author

Brancaccio, Rosario N., primary, Robitaille, Alexis, additional, Dutta, Sankhadeep, additional, Cuenin, Cyrille, additional, Santare, Daiga, additional, Skenders, Girts, additional, Leja, Marcis, additional, Fischer, Nicole, additional, Giuliano, Anna R., additional, Rollison, Dana E., additional, Grundhoff, Adam, additional, Tommasino, Massimo, additional, and Gheit, Tarik, additional

Published
2018
Full Text
View/download PDF

17. FIT test-systems for mega-scale gut microbiome testing

Author

Gudra, Dita, primary, Fridmanis, Davids, additional, Klovins, Janis, additional, Skenders, Girts, additional, Silamikelis, Ivars, additional, Radovica-Spalvina, Ilze, additional, Peculis, Raitis, additional, Kalnina, Ineta, additional, Elbere, Ilze, additional, Hultcrantz, Rolf, additional, Leja, Marcis, additional, and Engstrand, Lars, additional

Published
2017
Full Text
View/download PDF

18. Tuberculosis cases caused by heterogeneous infection in Eastern Europe and their influence on outcomes

Author

Kontsevaya, Irina, primary, Nikolayevskyy, Vladyslav, additional, Kovalyov, Alexander, additional, Ignatyeva, Olga, additional, Sadykhova, Anna, additional, Simak, Tatiana, additional, Tikhonova, Olesya, additional, Dubrovskaya, Yulia, additional, Vasiliauskiene, Edita, additional, Davidaviciene, Edita, additional, Skenders, Girts, additional, Makurina, Olga, additional, Balabanova, Yanina, additional, and Drobniewski, Francis, additional

Published
2017
Full Text
View/download PDF

19. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages

Author

Stucki, David, primary, Brites, Daniela, additional, Jeljeli, Leïla, additional, Coscolla, Mireia, additional, Liu, Qingyun, additional, Trauner, Andrej, additional, Fenner, Lukas, additional, Rutaihwa, Liliana, additional, Borrell, Sonia, additional, Luo, Tao, additional, Gao, Qian, additional, Kato-Maeda, Midori, additional, Ballif, Marie, additional, Egger, Matthias, additional, Macedo, Rita, additional, Mardassi, Helmi, additional, Moreno, Milagros, additional, Vilanova, Griselda Tudo, additional, Fyfe, Janet, additional, Globan, Maria, additional, Thomas, Jackson, additional, Jamieson, Frances, additional, Guthrie, Jennifer L, additional, Asante-Poku, Adwoa, additional, Yeboah-Manu, Dorothy, additional, Wampande, Eddie, additional, Ssengooba, Willy, additional, Joloba, Moses, additional, Boom, W Henry, additional, Basu, Indira, additional, Bower, James, additional, Saraiva, Margarida, additional, Vasconcellos, Sidra E G, additional, Suffys, Philip, additional, Koch, Anastasia, additional, Wilkinson, Robert, additional, Gail-Bekker, Linda, additional, Malla, Bijaya, additional, Ley, Serej D, additional, Beck, Hans-Peter, additional, de Jong, Bouke C, additional, Toit, Kadri, additional, Sanchez-Padilla, Elisabeth, additional, Bonnet, Maryline, additional, Gil-Brusola, Ana, additional, Frank, Matthias, additional, Penlap Beng, Veronique N, additional, Eisenach, Kathleen, additional, Alani, Issam, additional, Ndung'u, Perpetual Wangui, additional, Revathi, Gunturu, additional, Gehre, Florian, additional, Akter, Suriya, additional, Ntoumi, Francine, additional, Stewart-Isherwood, Lynsey, additional, Ntinginya, Nyanda E, additional, Rachow, Andrea, additional, Hoelscher, Michael, additional, Cirillo, Daniela Maria, additional, Skenders, Girts, additional, Hoffner, Sven, additional, Bakonyte, Daiva, additional, Stakenas, Petras, additional, Diel, Roland, additional, Crudu, Valeriu, additional, Moldovan, Olga, additional, Al-Hajoj, Sahal, additional, Otero, Larissa, additional, Barletta, Francesca, additional, Carter, E Jane, additional, Diero, Lameck, additional, Supply, Philip, additional, Comas, Iñaki, additional, Niemann, Stefan, additional, and Gagneux, Sebastien, additional

Published
2016
Full Text
View/download PDF

23. Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis

Author

Cegielski, J. Peter, primary, Dalton, Tracy, additional, Yagui, Martin, additional, Wattanaamornkiet, Wanpen, additional, Volchenkov, Grigory V., additional, Via, Laura E., additional, Van Der Walt, Martie, additional, Tupasi, Thelma, additional, Smith, Sarah E., additional, Odendaal, Ronel, additional, Leimane, Vaira, additional, Kvasnovsky, Charlotte, additional, Kuznetsova, Tatiana, additional, Kurbatova, Ekaterina, additional, Kummik, Tiina, additional, Kuksa, Liga, additional, Kliiman, Kai, additional, Kiryanova, Elena V., additional, Kim, HeeJin, additional, Kim, Chang-ki, additional, Kazennyy, Boris Y., additional, Jou, Ruwen, additional, Huang, Wei-Lun, additional, Ershova, Julia, additional, Erokhin, Vladislav V., additional, Diem, Lois, additional, Contreras, Carmen, additional, Cho, Sang Nae, additional, Chernousova, Larisa N., additional, Chen, Michael P., additional, Caoili, Janice Campos, additional, Bayona, Jaime, additional, Akksilp, Somsak, additional, Calahuanca, Gloria Yale, additional, Wolfgang, Melanie, additional, Viiklepp, Piret, additional, Vasilieva, Irina A., additional, Taylor, Allison, additional, Tan, Kathrine, additional, Suarez, Carmen, additional, Sture, Ingrida, additional, Somova, Tatiana, additional, Smirnova, Tatyana G., additional, Sigman, Erika, additional, Skenders, Girts, additional, Sitti, Wanlaya, additional, Shamputa, Isdore C., additional, Riekstina, Vija, additional, Pua, Kristine Rose, additional, Therese, M., additional, Perez, C., additional, Park, Seungkyu, additional, Norvaisha, Inga, additional, Nemtsova, Evgenia S., additional, Min, Seonyeong, additional, Metchock, Beverly, additional, Levina, Klavdia, additional, Lei, Yung-Chao, additional, Lee, Jongseok, additional, Larionova, Elena E., additional, Lancaster, Joey, additional, Jeon, Doosoo, additional, Jave, Oswaldo, additional, Khorosheva, Tatiana, additional, Hwang, Soo Hee, additional, Huang, Angela Song-En, additional, Gler, M. Tarcela, additional, Dravniece, Gunta, additional, Eum, Seokyong, additional, Demikhova, Olga V., additional, Degtyareva, Irina, additional, Danilovits, Manfred, additional, Cirula, Anda, additional, Cho, Eunjin, additional, Cai, Ying, additional, Brand, Jeanette, additional, Bonilla, Cesar, additional, Barry, Clifton E., additional, Asencios, Luis, additional, Andreevskaya, Sofia N., additional, and Akksilp, Rattanawadee, additional

Published
2014
Full Text
View/download PDF

24. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

Author

Skripconoka, Vija, primary, Danilovits, Manfred, additional, Pehme, Lea, additional, Tomson, Tarmo, additional, Skenders, Girts, additional, Kummik, Tiina, additional, Cirule, Andra, additional, Leimane, Vaira, additional, Kurve, Anu, additional, Levina, Klavdia, additional, Geiter, Lawrence J., additional, Manissero, Davide, additional, and Wells, Charles D., additional

Published
2012
Full Text
View/download PDF

26. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages

Author

Fenner, Lukas, Vilanova, Griselda Tudo, Bower, James, Wilkinson, Robert, Gehre, Florian, Borrell, Sonia, Alani, Issam, Malla, Bijaya, Wampande, Eddie, Gao, Qian, Akter, Suriya, Stewart-Isherwood, Lynsey, Koch, Anastasia, Trauner, Andrej, Cirillo, Daniela Maria, Sanchez-Padilla, Elisabeth, Ntoumi, Francine, De Jong, Bouke C, Supply, Philip, Suffys, Philip, Hoelscher, Michael, Luo, Tao, Niemann, Stefan, Gil-Brusola, Ana, Eisenach, Kathleen, Joloba, Moses, Asante-Poku, Adwoa, Brites, Daniela, Stucki, David, Crudu, Valeriu, Kato-Maeda, Midori, Ballif, Marie, Comas, Iñaki, Barletta, Francesca, Otero, Larissa, Bakonyte, Daiva, Fyfe, Janet, Stakenas, Petras, Globan, Maria, Ndung'u, Perpetual Wangui, Moldovan, Olga, Penlap Beng, Veronique N, Beck, Hans-Peter, Liu, Qingyun, Diel, Roland, Thomas, Jackson, Moreno, Milagros, Al-Hajoj, Sahal, Basu, Indira, Toit, Kadri, Rutaihwa, Liliana, Saraiva, Margarida, Boom, W Henry, Revathi, Gunturu, Skenders, Girts, Ntinginya, Nyanda E, Ley, Serej D, Hoffner, Sven, Macedo, Rita, Bonnet, Maryline, Gail-Bekker, Linda, Carter, E Jane, Guthrie, Jennifer L, Coscolla, Mireia, Ssengooba, Willy, Jamieson, Frances, Gagneux, Sebastien, Rachow, Andrea, Mardassi, Helmi, Diero, Lameck, Jeljeli, Leïla, Yeboah-Manu, Dorothy, Frank, Matthias, Vasconcellos, Sidra E G, and Egger, Matthias

Subjects
610 Medicine & health, 360 Social problems & social services, 3. Good health

28. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Author

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, and Smirnova TG

Subjects
Adolescent, Adult, Aged, Drug Resistance, Multiple, Bacterial, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis isolation & purification, Prospective Studies, Sputum microbiology, Treatment Outcome, Young Adult, Antitubercular Agents therapeutic use, Mycobacterium tuberculosis drug effects, Tuberculosis, Multidrug-Resistant drug therapy
Abstract

Background: Resistance to second-line drugs develops during treatment of multidrug-resistant (MDR) tuberculosis, but the impact on treatment outcome has not been determined., Methods: Patients with MDR tuberculosis starting second-line drug treatment were enrolled in a prospective cohort study. Sputum cultures were analyzed at a central reference laboratory. We compared subjects with successful and poor treatment outcomes in terms of (1) initial and acquired resistance to fluoroquinolones and second-line injectable drugs (SLIs) and (2) treatment regimens., Results: Of 1244 patients with MDR tuberculosis, 973 (78.2%) had known outcomes and 232 (18.6%) were lost to follow-up. Among those with known outcomes, treatment succeeded in 85.8% with plain MDR tuberculosis, 69.7% with initial resistance to either a fluoroquinolone or an SLI, 37.5% with acquired resistance to a fluoroquinolone or SLI, 29.3% with initial and 13.0% with acquired extensively drug-resistant tuberculosis (P < .001 for trend). In contrast, among those with known outcomes, treatment success increased stepwise from 41.6% to 92.3% as the number of drugs proven effective increased from ≤1 to ≥5 (P < .001 for trend), while acquired drug resistance decreased from 12% to 16% range, depending on the drug, down to 0%-2% (P < .001 for trend). In multivariable analysis, the adjusted odds of treatment success decreased 0.62-fold (95% confidence interval, .56-.69) for each increment in drug resistance and increased 2.1-fold (1.40-3.18) for each additional effective drug, controlling for differences between programs and patients. Specific treatment, patient, and program variables were also associated with treatment outcome., Conclusions: Increasing drug resistance was associated in a logical stepwise manner with poor treatment outcomes. Acquired resistance was worse than initial resistance to the same drugs. Increasing numbers of effective drugs, specific drugs, and specific program characteristics were associated with better outcomes and less acquired resistance., (Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.)

Published
2016
Full Text
View/download PDF

29. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Author

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, and Wells CD

Subjects
Adolescent, Adult, Drug Administration Schedule, Extensively Drug-Resistant Tuberculosis mortality, Female, Follow-Up Studies, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome, Tuberculosis, Multidrug-Resistant mortality, Young Adult, Antitubercular Agents therapeutic use, Extensively Drug-Resistant Tuberculosis drug therapy, Nitroimidazoles therapeutic use, Oxazoles therapeutic use, Tuberculosis, Multidrug-Resistant drug therapy
Abstract

Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis. Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant disease. Patients who participated in the previously reported randomised, placebo-controlled trial of delamanid and the subsequent open-label extension trial were eligible to participate in a 24-month observational study designed to capture treatment outcomes. Treatment outcomes, as assessed by clinicians and defined by the World Health Organization, were categorised as favourable and unfavourable. Delamanid treatment groups were combined for analysis, based on their duration of treatment. In total, for 421 (87.5%) out of 481 patients from the original randomised controlled trial, consent was granted for follow-up assessments. Favourable outcomes were observed in 143 (74.5%) out of 192 patients who received delamanid for ≥6 months, compared to 126 (55%) out of 229 patients who received delamanid for ≤2 months. Mortality was reduced to 1.0% among those receiving long-term delamanid versus short-term/no delamanid (8.3%; p<0.001). Treatment benefit was also seen among patients with extensively drug-resistant TB. This analysis suggests that treatment with delamanid for 6 months in combination with an optimised background regimen can improve outcomes and reduce mortality among patients with both multidrug-resistant and extensively drug-resistant TB.

Published
2013
Full Text
View/download PDF

30. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.

Author

Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H, Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, and Viiklepp P

Subjects
Adolescent, Adult, Aged, Extensively Drug-Resistant Tuberculosis drug therapy, Extensively Drug-Resistant Tuberculosis epidemiology, Female, Humans, Male, Middle Aged, Prevalence, Risk Factors, Socioeconomic Factors, Tuberculosis, Multidrug-Resistant epidemiology, Young Adult, Antitubercular Agents therapeutic use, Tuberculosis, Multidrug-Resistant drug therapy
Abstract

Background: The prevalence of extensively drug-resistant (XDR) tuberculosis is increasing due to the expanded use of second-line drugs in people with multidrug-resistant (MDR) disease. We prospectively assessed resistance to second-line antituberculosis drugs in eight countries., Methods: From Jan 1, 2005, to Dec 31, 2008, we enrolled consecutive adults with locally confirmed pulmonary MDR tuberculosis at the start of second-line treatment in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea, and Thailand. Drug-susceptibility testing for study purposes was done centrally at the Centers for Disease Control and Prevention for 11 first-line and second-line drugs. We compared the results with clinical and epidemiological data to identify risk factors for resistance to second-line drugs and XDR tuberculosis., Findings: Among 1278 patients, 43·7% showed resistance to at least one second-line drug, 20·0% to at least one second-line injectable drug, and 12·9% to at least one fluoroquinolone. 6·7% of patients had XDR tuberculosis (range across study sites 0·8-15·2%). Previous treatment with second-line drugs was consistently the strongest risk factor for resistance to these drugs, which increased the risk of XDR tuberculosis by more than four times. Fluoroquinolone resistance and XDR tuberculosis were more frequent in women than in men. Unemployment, alcohol abuse, and smoking were associated with resistance to second-line injectable drugs across countries. Other risk factors differed between drugs and countries., Interpretation: Previous treatment with second-line drugs is a strong, consistent risk factor for resistance to these drugs, including XDR tuberculosis. Representative drug-susceptibility results could guide in-country policies for laboratory capacity and diagnostic strategies., Funding: US Agency for International Development, Centers for Disease Control and Prevention, National Institutes of Health/National Institute of Allergy and Infectious Diseases, and Korean Ministry of Health and Welfare., (Copyright © 2012 Elsevier Ltd. All rights reserved.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results